Blood versus crystalloid cardioplegia for myocardial protection of donor hearts during transplantation: A prospective, randomized clinical trial  by Luciani, Giovanni Battista et al.
has allowed extension of heart transplantation to a
growing subset of high-risk recipients.2 Not surprising-
ly, acute failure of the graft and elevated pulmonary
vascular resistance still account for most early deaths
after transplantation.3 These observations have promot-
ed a revived interest for methods to protect the heart
from ischemia during transplantation. A review by
Wheeldon and associates4 has underscored the great
diversity of techniques used for myocardial preserva-
tion. Based on an exhaustive body of experimental evi-
dence,5-9 a trend toward the application of myocardial
reperfusion with the use of blood cardioplegia during
heart transplantation is gradually emerging.4 More
recently, a novel method to protect the heart, which
includes induction with blood cardioplegia in the donor
T he need for continued extension of donor selectioncriteria to meet the demand for heart transplantation
is leading to increasing acceptance of “marginal”
grafts.1 At the same time, progress in the management
of pretransplantation and posttransplantation morbidity
Objective: To assess the safety and efficacy of myocardial protection of the
donor heart during transplantation with the use of blood cardioplegia,
a prospective randomized clinical trial was undertaken between
January 1997 and March 1998. Methods: Forty-seven consecutive
patients were assigned either to crystalloid (27 patients; group 1) or
blood cardioplegia (20 patients; group 2). Comparison of recipient age
(54 ± 11 years vs 55 ± 7 years; P = .9), sex (89% vs 90% male patients;
P = .9), diagnosis (63% vs 65% dilated cardiomyopathy; P = .8), elevat-
ed pulmonary vascular resistance (30% vs 30%; P = .9), prior cardiac
operations (22% vs 30%; P = .5), need for urgent heart transplantation
(7% vs 20%; P = .2), donor age (32 ± 11 years vs 31 ± 13 years; P = .7),
cause of death (33% vs 40% vascular; P = .5), and global myocardial
ischemia (176 ± 51 minutes vs 180 ± 58 minutes; P = .5) showed no dif-
ference. Hemodynamically unstable donors (15% vs 45%; P = .02) were
more prevalent in group 2. Results: Operative mortality rates (4% vs
5%; P = .8), high-dose inotropic support (41% vs 30%; P = 0.6), and
postoperative mechanical assistance (11% vs 10%; P = 0.9) were com-
parable in the 2 groups. Prevalence of acute right heart failure (27% vs
0; P = .02) and of temporary complete atrioventricular block (52% vs
20%; P = .02) were greater in group 1. Spontaneous sinus rhythm recov-
ery was more prevalent in group 2 (11% vs 40%; P = .02). Higher peak
creatine kinase (1429 ± 725 u/L vs 868 ± 466 u/L; P = .01) and creatine
kinase MB (144 ± 90 u/L vs 102 ± 59 u/L; P = .06) levels suggested more
severe ischemic injury in group I. Conclusion: Use of blood cardioplegia
was associated with a lower prevalence of right heart failure, cardiac
rhythm dysfunction, and laboratory evidence of ischemia. (J Thorac
Cardiovasc Surg 1999;118:787-95)
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CARDIOTHORACIC TRANSPLANTATION
BLOOD VERSUS CRYSTALLOID CARDIOPLEGIA FOR MYOCARDIAL PROTECTION OF DONOR
HEARTS DURING TRANSPLANTATION: A PROSPECTIVE, RANDOMIZED CLINICAL TRIAL
and reperfusion in the recipient, has shown promising
results.10 The purpose of the present study was to com-
pare the safety and efficacy of myocardial preservation
with the induction and reperfusion of blood cardiople-
gia with standard crystalloid cardioplegia.
Patients and methods
Study design. Since June 1995, myocardial protection of
the donor heart during transplantation was adopted. The tech-
nique was initially applied in a nonrandomized fashion. On
the basis of the encouraging preliminary results observed in
21 selected recipients,10 a prospective, randomized clinical
trial was initiated. Between January 1997 and March 1998,
all consecutive patients undergoing heart transplantation were
asked to participate in the study. All 49 recipients who under-
went transplantation during this time interval expressed their
consent to the investigation and comprise the study popula-
tion of this report. Two of the 49 patients were excluded
because they underwent heterotopic heart transplantation.
Random assignment to either standard (crystalloid; group 1)
or modified (blood; group 2) cardioplegia was done accord-
ing to the last digit (even versus odd number) of the medical
record number of the patient.
Operative technique. All patients underwent orthotopic
heart transplantation with the use of a modified technique,
which entails left atrial cuff and direct bicaval anastomosis, as
described by Blanche and associates.11 Briefly, the donor
underwent routine standard orthotopic heart transplantation.
Attention was paid to the transection of the superior vena
cava above the azygos vein. After donor heart was dissected,
a double-outlet needle (Research Medical Inc, Midvale,
Utah) was inserted in the donor’s ascending aorta and secured
with a 4-0 polypropylene purse-string suture. In group 1
patients, the needle was connected with standard St Thomas’
Hospital II solution used to achieve cardiac standstill
(Table I). Alternatively in group 2, 1 port of the needle was
connected with a disposable cardioplegia bag where donor
blood was collected and mixed with the Buckberg (A2) solu-
tion.8 The bag was connected with a heat exchanger
(Medtronic Bio-Medicus, Minneapolis, Minn) and a roller
pump, which was used to cool the solution to 10°C and to
infuse the solution at a constant pressure (60-80 mm Hg)
through a line connected with the second port of the cardio-
plegia needle. After heparin bolus administration (3 mg/kg),
800 to 1000 mL of donor blood was slowly allowed to drain
through the outflow port of the needle. Intercurrent episodes
of systemic hypotension were treated with colloid fluid
administration. The hematocrit of the induction solution was
kept around 24% (Table I). The aorta was then crossclamped,
and blood cardioplegic solution was administered through the
antegrade route; the heart was decompressed through the
right superior pulmonary vein and inferior vena cava. After
the heart was excised, the graft was stored in cold (0°C-4°C)
sterile saline solution. Recipient operation was performed
under moderately hypothermic cardiopulmonary bypass.
Attention was devoted to the site of caval cannulation, which
was immediately below the origin of the superior vena cava
and below the pericardial reflection of the inferior vena cava.
Excision of the heart was carried out by transection of the
superior vena cava at the atriocaval junction with a generous
cuff of right atrium around the inferior vena cava. After sec-
tion of the aorta and pulmonary artery trunk 2 cm above the
semilunar valves, a left atrial cuff around the 4 pulmonary
veins was tailored. Implantation of the graft was completed
by anastomosis of the left atrial cuff, followed by the inferior
vena cava, the main pulmonary artery, and the ascending
aorta. Before the exposure of the graft to the recipient’s own
blood, a methylprednisolone bolus (1000 mg) was given
intravenously. This time corresponded to aortic clamp release
in group 1 patients, who did not receive any form of reperfu-
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Table I. Composition of cardioplegic solutions
Crystalloid Buckberg A2 Buckberg C3
pH (room temperature) 7.6-7.8 7.5-7.7 7.5-7.7
Dose 15 mL/kg 15 mL/kg 150 mL · min–1 · m–2 for 3 min
Osmolarity (mOsm/L) 320 320 380
Temperature (°C) 10 10 34
Hematocrit (%) — 24 24
Na+ (mEq/L) 120 160 160
K+ (mEq/L) 16 70 30
Cl– (mEq/L) 160 170 30
HCO3– (mEq/L) 10 — —
Ca2+ (mEq/L) 2.4 1 1
Mg2+ (mEq/L) 32 — —
Glucose (g/L) — 36 36
THAM (mEq/L) — 70 70
CPD (mL) — 60 230
Glutamate (mEq/L) — — 60
Aspartate (mEq/L) — — 60
THAM, Tromethamine; CPD, citrate phosphate dextrose.
sion. In group 2 patients, the ascending aorta was again can-
nulated, and methylprednisolone was administered before
warm (34°C) antegrade reperfusion with blood cardioplegic
solution (Buckberg C3; Table I). Finally, the superior caval
anastomosis was performed after aortic clamp removal.
Postoperative management and patient follow-up 
Intraoperative management. Weaning from cardiopul-
monary bypass was routinely performed with the aid of low-
dose (5 m g · kg–1 · min–1) dopamine and isoproterenol (0.02
m g · kg–1 · min–1) infusion. An increase in the dose of cate-
cholamine and the addition of epinephrine infusion were con-
sidered in case of intraoperative low-output syndrome. Intra-
aortic balloon pump (IABP) and ventricular assist device
support were left as the last therapeutic measure in case of
refractory circulatory insufficiency. Perioperative right heart
failure was managed by mechanical hyperventilation and
infusion of prostaglandin E1 (0.01-0.1 m g · kg–1 · min–1). In
case of persistent right heart insufficiency, inhaled nitric
oxide therapy (5-40 ppm) was commenced.
Posttransplantation immunosuppressive therapy. The same
treatment protocol was applied to all recipients, regardless of
the technique used for preservation of the heart. The protocol
included oral cyclosporine (5-8 mg/kg per day) to maintain a
whole blood trough level of 300 to 500 ng/dL, azathioprine
(2-4 mg/kg per day) to maintain a total white blood cell count
of 4000/mL, and oral prednisone (starting at a maintenance
dose of 1 mg/kg per day and tapered to 0.5 mg/kg per day by
month 3). Discontinuation of chronic steroid therapy was
attempted after posttransplantation month 6. Surveillance of
rejection was performed with a schedule of programmed
endomyocardial biopsies, and treatment of a rejection was by
means of pulse doses of methylprednisolone and/or augmen-
tation of immunosuppression on an individual basis. Patient
follow-up was based on examination during routine admis-
sions for laboratory investigations, including endomyocardial
biopsies, and was 100% complete. 
Definition of variables and statistical analysis. Urgent
heart transplantation was defined as any heart transplantation
performed for in-hospital recipients who were receiving
intravenous infusion of inotropic drugs and/or supported with
IABP or ventricular assist device. Hemodynamic instability
in the donor was defined as the presence of at least 1 episode
of cardiac arrest or sustained (longer than 10 minutes) pro-
found hypotension (≤50 mm Hg systolic pressure) requiring
resuscitation, and/or the need for 2 or more inotropic agents,
and/or the presence of supraventricular or ventricular tach-
yarrhythmias leading to hypotension (≤50 mm Hg systolic
pressure) requiring either pharmacologic or electrical car-
dioversion. End points of the study were operative death (any
death within 30 days or before discharge), the need for high-
dose inotropic support (3 inotropic agents or 2 inotropic
agents, 1 of which is epinephrine), mechanical life support
(IABP, ventricular assist device), acute right heart failure
(central venous pressure, >18 mm Hg; cardiac index, <2.0 L
· min–1 · m–2; left atrial pressure, <10 mm Hg; urine output,
<1 mL · kg–1 · h–1), acute graft failure (need for high-dose
inotropic and/or mechanical life support in the absence of
right heart failure), ventricular kinetics and shortening frac-
tion at predischarge echocardiographic examination, sponta-
neous sinus rhythm recovery (resumption after clamp
removal), induced sinus rhythm recovery (after intraoperative
cardioversion), temporary complete atrioventricular block
(need for temporary pacing of any duration, with recovery of
sinus rhythm before discharge), permanent complete atrio-
ventricular block (requiring permanent pacing), duration of
ventilatory support, duration of intensive care stay, peak total
and isoenzyme MB creatine kinase blood level, prevalence of
histologic evidence of ischemia at first endomyocardial biop-
sy, late death, actuarial survival. 
Values were expressed as mean ± SD. The c 2 test was used
to compare the distribution of binary variables, although the
2-tailed Student t test was used for comparison of continuous
variables. Actuarial survival was calculated with the Kaplan-
Meier product limit estimate, and curves were compared by
means of the log-rank test. A P value less than .05 was con-
sidered indicative of a difference between variables not attrib-
uted to chance alone.
The Journal of Thoracic and
Cardiovascular Surgery
Volume 118, Number 5
Luciani et al   789
Table II. Recipient and donor profile
Group 1 Group 2 P value
Patients (n) 27 20
Recipient male sex (%) 89 (24/27) 90 (18/20) .9
Recipient mean age (y) 54 ± 11 55 ± 7 .9
Diagnosis of dilated cardiomyopathy (%) 63 (17/27) 65 (13/20) .8
Recipient elevated PVR, >4 Wood units (%) 30 (8/27) 30 (6/20) .9
Prior cardiac operation (%) 22 (6/27) 30 (6/20) .5
Urgent heart transplantation (%) 7 (2/27) 20 (4/20) .2
Donor male sex (%) 78 (21/27) 70 (14/20) .5
Donor mean age (y) 32 ± 11 31 ± 13 .7
Donor vascular death (%) 33 (9/27) 45(9/20) .5
Unstable donor hemodynamics (%) 15 (4/27) 45 (9/20) .02
Ischemic time (min) 176 ± 51 180 ± 58 .8
Bypass time (min) 135 ± 34 128 ± 23 .5
PVR, Pulmonary vascular resistance.
Results 
Recipient and donor population. Forty-seven
patients qualified for the study; 27 patients received
standard (crystalloid) cardioplegia, and 20 patients
received modified (blood) cardioplegia for myocardial
protection of their graft (Table II). Analysis of recipient
demographic variables disclosed no significant differ-
ence. History of prior cardiac surgical procedures and
of pulmonary hypertension were equally represented in
the 2 groups. Need for urgent heart transplantation was
3-fold more common in group 2 recipients, although
the difference did not reach statistical significance. The
47 donors assigned to recipients in the study also pre-
sented comparable demographic variables except for
unstable hemodynamics, which was more prevalent in
donors assigned to the modified myocardial protection.
Bypass and ischemic times were similar; the latter ones
averaged 3 hours in both groups.
Survival and graft failure. There was 1 early death
in each group (4% [1/27 patients] vs 5% [1/20
patients]; P = .80); both patients had undergone opera-
tion on an urgent basis (Table III). The patient in group
1 was a 49-year-old man with ischemic cardiomyopa-
thy (left ventricular ejection fraction, 20%), in whom
postcardiotomy acute left ventricular failure developed
after elective myocardial revascularization. After 6
days of mechanical life support with the use of a left
ventricular assist device (LVAD) and IABP, the patient
underwent heart transplantation. Weaning from bypass
required the resumption of mechanical life support with
LVAD and IABP because of acute graft failure. Shortly
after the heart transplantation, the patient experienced
the development of irreversible circulatory shock,
which was caused by massive pulmonary embolism,
which was found at postmortem examination. The
patient in group 2 was a 45-year-old man with a history
of treated Hodgkin lymphoma and an irradiation/
chemotherapy-induced cardiomyopathy and chronic
renal failure. Urgent heart transplantation was advised
because of an acute congestive failure episode requir-
ing in-hospital intravenous inotropic support. One week
after successful heart transplantation, rapidly progress-
ing renal failure developed, which required daily dialy-
sis. The patient had a fatal, massive gastrointestinal
hemorrhage during dialytic treatment 2 months after
heart transplantation.
Prevalence of postoperative graft dysfunction, as
gathered from the need for high-dose inotropic support
(41% [11/27 patients] vs 30% [6/20 patients]; P = .50)
and for mechanical life support (11% [3/27 patients] vs
10% [2/20 patients]; P = .90) was comparable in the 2
groups (Table III). Three patients in group 1 required
mechanical support, including the 1 patient who died
early. In detail, 1 patient required IABP and 1 patient
required IABP and LVAD, respectively, for left heart
failure; the third patient needed IABP and a right ven-
tricular assist device for acute right heart failure. In
group 2, 2 patients required IABP, both for acute left
heart failure. The prevalence of acute graft failure was
comparable between groups (15% [4/27 patients] vs
30% [6/20 patients]; P = .30). On the contrary, an
analysis of right heart failure showed a significantly
higher prevalence among group 1 recipients (26%
[7/27 patients] vs 0% [0/22 patients]; P = .02). In addi-
tion, 3 of the 7 patients (43%) with acute right-sided
insufficiency required advanced circulatory support,
which included inhaled nitric oxide therapy in 2
patients and a right ventricular assist device in 1 patient
(Table III). Assessment of ventricular function by
means of 2-dimensional echocardiography before
hospital discharge revealed a comparable shorten-
ing fraction of the left ventricle in the 2 groups.
However, prevalence of at least moderate either right or
left ventricular dysfunction, as judged by the severity
of hypokinesis at 2-dimensional echocardiography,
seemed higher in recipients who had crystalloid car-
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Table III. Survival and graft function
Group 1 Group 2 P value
Early mortality (%) 4 (1/27) 4 (1/20) .8
High-dose inotropic support (%) 41 (11/27) 30 (6/20) .6
Mechanical life support (%) 11 (3/27) 10 (2/20) .9
Acute graft failure (%) 15 (4/27) 30 (6/20) .2
Acute right heart failure (%) 26 (7/27) 0 (0/20) .01
Left ventricular shortening fraction (%) 32.8 ± 6.1 34.1 ± 5.8 .4
Left ventricular dysfunction (%) 11 (3/27) 0 (0/20) .1
Right ventricular dysfunction (%) 11 (3/27) 0 (0/20) .1
Late mortality (%) 0 (0/26) 5 (1/19) .2
Follow-up (mo) 13.7 ± 4.8 15.0 ± 4.9 .7
dioplegia, although the estimate did not reach statisti-
cal significance (Table III).
Electrophysiologic findings. Electrophysiologic
findings were significantly different between the 2
patient groups (Table IV). Both spontaneous sinus
rhythm recovery on aortic clamp removal (11% [3/27
patients] vs 40% [8/20 patients]; P = .02) and immedi-
ate recovery of regular atrioventricular conduction
were more common in patients in group 2, as evi-
denced by the reduced need for temporary atrioventric-
ular pacing (52% [14/27 patients] vs 20% [4/20
patients]; P = .02). In addition, the duration of the tem-
porary atrioventricular block was significantly shorter
in group 2 patients (1.6 ± 0.9 days vs 3.2 ± 2.6 days; P
= .05). No patient in the group 2 versus 1 patient in
group 1 required permanent pacing for complete atri-
oventricular block. The prevalence of minor conduc-
tion disturbances such as incomplete and complete
right bundle branch block proved comparable in the 2
groups (Table IV).
Posttransplantation ischemia. Laboratory evidence
of myocardial ischemia, as assessed by creatine kinase
MB blood levels after heart transplantation, disclosed
higher creatine kinase MB values in group 1 recipients
at 6 hours, although the difference was marginally sig-
nificant (144 ± 90 u/L vs 102 ± 59 u/L; P = .06) (Table
V). The difference was not significant at 24 hours. On
the contrary, blood levels of total creatine kinase, both
at 6 and 24 hours, were significantly higher in group 1
recipients, suggesting greater generalized tissue injury.
Histologic findings compatible with ischemic changes
at the first endomyocardial biopsy tended to be more
prevalent in group 1 recipients, although the difference
did not reach statistical significance (54% [14/26
patients] vs 30% [6/20 patients]; P = .13).
Postoperative recovery and follow-up. The mean
duration of mechanical ventilatory support was longer
in group 1 recipients, although the figure did not reach
statistical significance (33 ± 60 hours vs 25 ± 24 hours;
P = .58; Table III). The duration of intensive care unit
stay was comparable in the 2 groups, because of an
institutional policy to keep the heart transplantation
recipients in the unit until the day of the first endomy-
ocardial biopsy (6.8 ± 6.3 days vs 6.8 ± 3.6 days; P =
.98), thereby diminishing the importance of this index
for the purpose of comparing outcome. Follow-up of
hospital survivors ranged from 6 to 18 months, with no
significant difference between the 2 groups (15.0 ± 4.9
months vs 13.7 ± 4.8 months; P = .70). There was only
1 late death in the modified protection group (0% [0/26
patients] vs 5% [1/19 patients]; P = .30) of noncardiac
origin. The patient died 5 months after the transplanta-
tion of massive pulmonary embolism after an appen-
dectomy procedure. Actuarial survival at 1 year was
higher in group 1 (96% vs 90%) although the differ-
ence was not significant.
Discussion
The present prospective, randomized trial demon-
strates that the prevalence of acute right heart failure
and of atrioventricular conduction disturbance after
heart transplantation are lower when induction and
reperfusion blood cardioplegia are used for myocardial
protection. The study, nevertheless, suggests that both
The Journal of Thoracic and
Cardiovascular Surgery
Volume 118, Number 5
Luciani et al   791
Table IV. Electrophysiologic findings
Group 1 Group 2 P value
Spontaneous sinus rhythm recovery (%) 11 (3/27) 40 (8/20) .02
Temporary atrioventricular block (%) 52 (14/27) 20 (4/20) .02
Duration of atrioventricular block (d) 3.2 ± 2.6 1.6 ± 0.9 .05
Permanent atrioventricular block (%) 4 (1/26) (0/21) .3
Incomplete right bundle branch block (%) 22 (6/27) 15 (3/20) .2
Complete right bundle branch block (%) 33 (9/27) 30 (6/20) .8
Table V. Indices of myocardial ischemia
Group 1 Group 2 P value
CK-MB: hour 6 after transplantation (u/L) 144 ± 90 102 ± 59 .06
CK-MB: hour 24 after transplantation (u/L) 116 ± 83 100 ± 42 .7
CK: hour 6 after transplantation (u/L) 1430 ± 725 868 ± 466 .01
CK: hour 24 after transplantation (u/L) 1440 ± 851 832 ± 366 .02
Ischemic changes at EMB (%) 54 (14/26) 30 (6/20) .1
CK, Creatine kinase; MB, MB isoenzyme; EMB, endomyocardial biopsy.
crystalloid and blood cardioplegic solutions allow sat-
isfactory myocardial protection because the overall
clinical outcome is similar in the 2 groups and com-
pares well with currently reported results after heart
transplantation.3
The necessity to improve methods of myocardial pro-
tection during heart transplantation is dictated by clini-
cal evidence that suggests that acute graft failure
remains a leading cause of early posttransplantation
death.3 Indeed, the recent extension of donor selection
criteria, including the use of marginal donor organs,1
can in part explain the inability to reduce the preva-
lence of acute graft failure. In addition, the continued
expansion of the recipient pool, because of improve-
ments in the management of posttransplantation com-
plications, has selected a growing number of high-risk
candidates, which further exacerbates the conse-
quences of acute failure of the graft.2 These considera-
tions fully explain the crucial role of adequate myocar-
dial protection in the current era.4
Investigations of innovative methods to protect the
heart during heart transplantation have initially focused
on the relative benefits of various crystalloid solutions.
These solutions essentially differ in ionic composition,
thereby resembling alternatively the intracellular
milieu, the extracellular milieu, or an intermediate
environment.12-16 In spite of promising laboratory evi-
dence that shows superior protection with the use of
intracellular-like cardioplegic solutions,12 available
randomized clinical trials have been rare and have
yielded conflicting evidence.13-17 Indeed, although 2
prospective, randomized trials have demonstrated
improved early results with the use of University of
Wisconsin solution, albeit limited to prevalence of
arrhythmias and release of creatine kinase,14,15 further
experimental studies have lessened the relevance of
those findings.16 In addition, the use of intracellular
solutions has been postulated to cause chemical dam-
age to the coronary endothelium to explain the
observed higher prevalence of allograft vasculopathy.17
At the same time, growing laboratory evidence has sug-
gested a beneficial role for blood-based cardioplegic
solutions in heart transplantation.6-9 Moving from
Buckberg’s original work5 on the use of blood cardio-
plegia for myocardial protection in cardiac surgical
procedures, several groups have documented superior
myocardial protection during heart transplantation in
laboratory animals with the use of both blood cardio-
plegia for reperfusion6,7,9 and warm blood cardioplegia
for the induction of cardiac standstill.8 These observa-
tions account for the emerging trend toward the use of
some form of reperfusion in clinical heart transplanta-
tion, as reported by Wheeldon and associates.4
The application of blood cardioplegia to heart trans-
plantation is relatively recent, and a variety of methods
have thus far been adopted. Accordingly, Soots and
associates18 and Nataf and associates19 have reported
on the use of crystalloid cardioplegia induction, fol-
lowed by cold blood maintenance in the graft and warm
blood reperfusion before clamp removal. Although
Soots and associates18 have found significantly lower
mortality rates in patients receiving blood compared
with those patients with crystalloid cardioplegia, the
estimates reported for both the control and the treat-
ment group are excessively high (21% vs 10%). In
addition, even early survival (50% ± 8% vs 64% ± 8%
at 18 months) appears well below the accepted standard
results after heart transplantation. In that study, factors
other than myocardial protection must have played a
relevant role. Likewise, the work by Nataf and associ-
ates19 shows prohibitive early mortality rates (20%
with the crystalloid versus 14% with the blood solu-
tion), although the rates are comparable in the 2
groups. The only significant difference reported is in
terms of sinus rhythm recovery and duration of inotrop-
ic support. Most important, both series are collected in
a retrospective, nonrandomized fashion, making even
the weak differences irrelevant. An alternative myocar-
dial protection strategy has been chosen by Pradas and
colleagues,20 who have reported on the use of cold
crystalloid induction and continuous retrograde reper-
fusion during implantation. When comparing this
method with standard crystalloid cardioplegia, the
authors have found a higher prevalence of spontaneous
sinus rhythm recovery, a lesser need for inotropic sup-
port, a shorter hospital stay, and a lower prevalence of
ischemic changes at endomyocardial biopsy.20 How-
ever, the ischemic time was significantly lower in
recipients of blood cardioplegia, and mortality was
twice as high (6% vs 14%). When added to the obser-
vation that this work is also retrospective and that the 2
patient groups were collected during different time
intervals, conclusions can hardly expand on anything
but the technical feasibility of the method.20
The only available prospective, randomized study on
blood cardioplegia in heart transplantation compares
the use of crystalloid induction and continuous retro-
grade warm blood reperfusion with standard crystalloid
induction in 34 consecutive heart transplant recipi-
ents.21 According to the authors, superiority of blood-
based cardioplegia can be inferred from the higher
prevalence of spontaneous defibrillation and the lower
prevalence of early graft failure, the other differences
not reaching statistical significance.21 Nonetheless, a
series of observations seem to weaken the conclusions.
The trial simultaneously compares 2 alternative solu-
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tions, administration routes and protocols. In addition,
mortality rate(18%) and prevalence of acute graft fail-
ure rate (24%) in the control group are excessively high
when matched with a short mean ischemic time
(approximately 2 hours) and a young average recipient
(47 ± 2 years) and donor (32 ± 2 years) age. These
results compare poorly with current operative mortali-
ty rates after heart transplantation, as reported by the
International Society for Heart and Lung Trans-
plantation,4 and with the authors’ own experience with
crystalloid cardioplegia before the randomized
study.21,22 It is reasonable to assume that factors other
than myocardial protection may have come into play
and that the results represent weak evidence favoring
the use of blood cardioplegia in heart transplantation.21
The present study attempts to provide more rigorous
information on the safety and efficacy of blood cardio-
plegia in heart transplantation. In an effort to simplify
a comparison between myocardial protection methods,
blood cardioplegic solutions in the donor and in the
recipient have been administered through the antegrade
route as for crystalloid cardioplegic solutions.10 The
original aspect of this technique is the use of blood car-
dioplegia to induce cardiac standstill in the donor, as
advocated by previous experimental work on donor
hearts with impaired hemodynamics8 and by routine
cardiac surgical practice.5 Compared with previous
randomized trials,14,15,21 the present series includes a
population of recipients with poorer pretransplantation
conditions, as attested by the overall prevalence of pul-
monary hypertension (30%), of prior cardiac opera-
tions (25%) and priority listing (12%), and a large pro-
portion of marginal donors (27% with unstable
hemodynamics). In addition, mean ischemic times are
longer than generally reported, with mean values
approximately 3 hours and extending to 5 hours of
preservation. Despite these considerations, overall
operative (2/47 patients; 4%) and late (1/45 patients;
2%) mortality rates favorably compare with current
standard results after heart transplantation.4 It can be
assumed that both the population and the outcome
described in this study are highly representative of the
current practice of heart transplantation worldwide. 
The present work demonstrates that both crystalloid
and blood cardioplegia are generally safe methods for
the protection of the myocardium during heart trans-
plantation, because both are associated with satisfacto-
ry early and late survival in a difficult cohort of recipi-
ents and with suboptimal or even marginal donor
organs. In detail, acute graft failure remains a definite
early hazard with both methods of myocardial protec-
tion, although it is usually reversible if pharmacologic
or mechanical support can effectively maintain the cir-
culation. The prevalence of acute graft failure with
blood cardioplegia appears slightly higher in our series
(6/20 patients; 30%) than previously reported with
other blood-based solutions (estimates ranging form
6% to 12%).19-21 It must be emphasized, however, that,
contrary to prior works, the definition of acute graft
failure herein was inclusive of patients who eventually
survived heart transplantation. Considering that no
patient in the blood cardioplegia group experienced
graft failure leading to death or retransplantation, our
results favorably compare with existing data.19-21 The
present study further demonstrates that failure of the
right heart is rare among recipients of blood cardiople-
gia but common among recipients of crystalloid car-
dioplegia; electrophysiologic changes typically associ-
ated with ischemia of the right heart (such as failure to
recover sinus rhythm and atrioventricular conduction)
are also rare. Acute right-sided circulatory insufficien-
cy, particularly in the face of elevated recipient pul-
monary vascular resistance, still represents a leading
cause of early death after heart transplantation.4 The
observations reported here are even more relevant con-
sidering that as much as one third of recipients enrolled
in the blood cardioplegia group had pretransplantation
pulmonary hypertension. The fact that none of the
cases of right-sided heart failure in the crystalloid car-
dioplegia group proved fatal is only indicative that
advanced life support, including the use of inhaled
nitric oxide and right ventricular assist devices (3 of 7
patients) may profoundly reduce the mortality rate in
high-risk transplant recipients. Comparison of our
results with previous studies is difficult with respect to
acute right heart failure, because this complication is
rarely quoted as such. Similarly to most series that sug-
gest benefits of blood-based cardioplegic solutions,18-21
the present work shows a higher prevalence of sponta-
neous sinus rhythm recovery and a lower prevalence of
atrioventricular conduction disturbance. The alleged
property of blood cardioplegia to enhance right heart
protection, including the conduction tissue, may
account for this finding. Although the overall preva-
lence of temporary atrioventricular block in the present
series appears rather high for heart transplantation with
the use of the bicaval anastomosis implantation tech-
nique, the overall need for permanent pacing (1/47
patients; 2%) was not significantly greater than esti-
mates reported by Trento and associates23 (0/100
patients) and identical to data presented by others24
(1/50 patients; 2%). These findings match with the lab-
oratory evidence of myocardial ischemia and with the
histologic findings that suggest greater ischemic dam-
age to the myocardium, albeit with a marginally signif-
icant difference. Comparison of these results with pre-
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vious reports is worthwhile, because a prior work by
Carrier and associates21 has shown levels of creatine
kinase MB, in transplant recipients who received crys-
talloid cardioplegia either with or without continuous
retrograde blood reperfusion, which are similar to those
found in recipients of crystalloid cardioplegia with no
reperfusion in our study. Thus induction with cold
blood and warm blood reperfusion gives better labora-
tory results of both crystalloid cardioplegia with no
reperfusion and crystalloid cardioplegia with continu-
ous retrograde blood reperfusion. 
The clinical implications of the present results seem
unclear from the study because overall outcome (death,
need for inotropic support, mechanical ventilation,
intensive care assistance) is comparable between
groups. However, more careful analysis of data shows
how recipients of blood cardioplegia were more com-
monly assigned marginal grafts (hemodynamically
unstable). One might speculate that the myocardial pro-
tection protocol adopted herein may enable the repro-
duction of the early outcome obtained with ideal donor
organs and ideal recipients even when large numbers of
marginal donor organs are used in poor heart transplan-
tation candidates. Accordingly, after the close of our
study, blood cardioplegia has been routinely used in the
presence of high-risk recipients (pulmonary hyperten-
sion, need for urgent transplantation, prior cardiac pro-
cedure), and/or marginal donor organs (donors older
than 40 years, unstable hemodynamics, distant retrieval).
Limitations. The present study is influenced by sev-
eral limitations. In fact, it reports the comparison of 2
different cardioplegic solutions and 2 different admin-
istration protocols (single induction versus induction
and reperfusion), even though the administration route
is the same (antegrade). The method requires the assis-
tance of a perfusion technician, although the protocol
can be performed without a portable pump, as well.
There may be potential for harm to other organs
because of the need for blood draw during the harvest-
ing procedure. Nevertheless, the 2 methods reported
herein reproduce the current standard for myocardial
protection in heart transplantation versus the applica-
tion of the Buckberg principles to heart transplantation.
Furthermore, additional costs connected with the
method may be balanced by decreased morbidity after
heart transplantation, provided this is demonstrated. No
organs were lost during the study from any of the 22
multiorgan donors who received induction blood car-
dioplegia.
In conclusion, the use of induction and reperfusion
blood cardioplegia is associated with lower prevalence
of posttransplantation right heart insufficiency, arrhyth-
mias, and laboratory evidence of ischemia when com-
pared with standard crystalloid cardioplegia. Adoption
of this method of myocardial protection may be indi-
cated to control early morbidity, particularly when poor
donor organs are used in high-risk transplant recipients.
We thank the perfusion technicians, Tiziano Menon,
Maddalena Tessari, Luigi Franchetto, Terenzio Marzocco,
and Francesco Faggionato for their assistance in developing
the myocardial protection protocol.
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